Elimination of unplanned treatment breaks and dose reductions caused by mucositis: Positive implications for survival outcomes and cost reductions using high potency polymerized cross-linked sucralfate in 55 patients undergoing radiation for head and neck cancer with and without chemotherapy
Korean Journal of Clinical Oncology
;
(2): 10-24, 2017.
Article
in English
| WPRIM
| ID: wpr-788002
ABSTRACT
PURPOSE:
Annually 27,855 patients in Korea develop treatment-induced mucositis nearly doubling the cost of cancer care. It is an emergency medical condition causing unplanned treatment breaks in 4,998 patients. The subsequent reduction in optimal dose-intensity causes premature deaths due to lower 5-year survival. An additional 216 patients die from mucositis-mediated sepsis and infection. Thus complete elimination of mucositis will immediately reduce the cost of care while simultaneously eliminating 5,214 mucositis-associated deaths. High potency polymerized cross-linked sucralfate (HPPCLS) cleared by the US Food and Drug Administration has been associated with the elimination of mucositis.METHODS:
Observational, self-reporting, practice-based mucositis registry. Inclusion criteria any patient with chemoradiation-induced mucositis. Exclusion criteria previous adverse reaction to sucralfate products. Primaryoutcome:
rapid reversal or complete prevention. Conduct of study 28 radiation oncologists from 21 different institutions prescribed HPPCLS to 55 patients undergoing chemoradiation for squamous cell carcinoma of head and neck and esophagus to eliminate mucositis-associated treatment breaks.RESULTS:
All patients with World Health Organization grade 1 (n=6), grade 2 (n=23), grade 3 (n=16) oral mucositis, and grade 2 esophageal mucositis (n=2) experienced complete reversal of mucositis. Within 2–3 days both mucosa and swallowing normalized. Anticipated grade 3/4 mucositis was prevented in 8 out of 8 elderly patients aged 78–93 avoiding gastrostomy tube placement. Statistical analysis ofoutcomes:
Outcomes qualified as a positive Glasziou treatment effect that was statistically significant (P<0.05).CONCLUSION:
HPPCLS eliminated mucositis by rapid reversal or complete prevention, thereby eliminating unplanned treatment breaks. It may likely reduce mucositis-associated increased cost of care and premature deaths.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Polymers
/
Stomatitis
/
United States Food and Drug Administration
/
World Health Organization
/
Sucralfate
/
Gastrostomy
/
Carcinoma, Squamous Cell
/
Sepsis
/
Deglutition
/
Drug Therapy
Type of study:
Health economic evaluation
Limits:
Aged
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Korean Journal of Clinical Oncology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS